Balance Sheet (Annual)

LANC / Lancaster Colony Corp. Balance Sheet shows account balances for the company at points in time. Balance Sheet data includes Assets, Current Assets, Fixed Assets, Property, Plant and Equipment (PPE), Inventory, Intangibles, Liabilities, Current Liabilities, Debt, Capital Lease Obligations, Common Stock, Retained Earnings, Treasury Stock, and Shareholders Equity.

All numbers are times 1,000 except per share units.

2012 2013 2014 2015 2016 2017
Assets
  Assets Current
    Cash And Cash Equivalents At Carrying Value 191,636 123,386 211,539 182,202 118,080 143,104
    Receivables Net Current 73,326 70,398 57,808 62,437 66,006 69,922
  Inventory Net
    Inventory Raw Materials Net Of Reserves 36,005 35,012 28,069 30,655 26,153 28,447
    Inventory Finished Goods Net Of Reserves - - 46,447 47,244 49,944 47,929
    Inventory Net 109,704 109,151 74,516 77,899 76,097 76,376
    Other Assets Current - - - - 7,644 11,744
    Assets Current 391,739 326,058 367,291 342,998 267,827 301,146
  Property Plant And Equipment Net
    Land Buildings And Improvements 140,337 144,206 107,690 113,844 116,858 124,673
    Machinery And Equipment Gross 276,951 289,051 238,791 253,143 263,336 272,582
    Property Plant And Equipment Gross 417,288 433,257 346,481 366,987 380,194 397,255
    Accumulated Depreciation Depletion And Amortization Property Plant And Equipment 233,158 243,562 177,807 194,676 210,599 216,584
    Property Plant And Equipment Net 184,130 189,695 168,674 172,311 169,595 180,671
    Other Assets Noncurrent
      Goodwill 89,840 89,840 89,840 143,788 143,788 168,030
      Finite Lived Intangible Assets Net 7,267 6,322 5,376 47,771 44,866 60,162
      Other Assets Noncurrent 9,659 8,049 7,449 8,076 8,656 6,396
  Assets 682,635 619,964 638,630 714,944 634,732 716,405
Liabilities And Stockholders Equity
  Liabilities Current
    Accounts Payable Current 40,708 41,890 37,907 38,823 39,931 41,353
    Accrued Liabilities Current 31,963 35,287 31,165 35,821 33,072 35,270
    Liabilities Current 72,671 77,177 69,072 74,644 73,003 76,623
  Other Liabilities Noncurrent 31,627 23,291 22,208 23,654 26,698 38,598
  Deferred Tax Liabilities Noncurrent 14,070 18,274 18,753 35,728 21,433 25,207
  Commitments And Contingencies - - - - - -
  Equity
    Preferred Stock Value Outstanding - - - - - -
    Common Stock Value 100,015 102,622 104,789 107,767 110,677 115,174
    Retained Earnings Accumulated Deficit 1,208,027 1,139,213 1,167,211 1,219,119 1,150,337 1,206,671
    Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax 12,162 8,391 8,061 10,057 11,350 8,936
    Treasury Stock Value 731,613 732,222 735,342 735,911 736,066 736,932
    Stockholders Equity 564,267 501,222 528,597 580,918 513,598 575,977
    Liabilities And Stockholders Equity 682,635 619,964 638,630 714,944 634,732 716,405

Peers - Canned, Frozen, And Preserved Fruits, Vegetables, and Food Specialties (203)

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 513847103